CDC’s Investments to Combat Antibiotic Resistance Threats Nationwide : Indiana
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All

CDC’s Investments to Combat Antibiotic Resistance Threats Nationwide : Indiana

Filetype[PDF-402.33 KB]

  • Description:
    $1,886,747 Funding for AR Activities Fiscal Year 2017 Candida auris, a resistant fungus that can cause deadly infections, was identified in Indiana. CDC provides Indiana with resources to identify and contain resistant infections, like C. auris. After C. auris emerged in the U.S. in 2016, the AR Lab Network regional labs also began providing specialized testing to states fighting this new threat. Funding to local health departments: $398,901 - RAPID DETECTION & RESPONSE to emerging drug-resistant germs is critical to contain the spread of these infections. With 2016 funding, Indiana investigated seven HAI/AR outbreaks with an average initial response time of two days. The State Laboratory and AR Epidemiologist identified and responded to 11 novel multidrug-resistant organisms, including one case of Candida auris and 10 cases of “nightmare bacteria” CRE. $324,726 - FOOD SAFETY projects protect communities by rapidly identifying drug-resistant foodborne bacteria to stop and solve outbreaks and improve prevention. Indiana implemented whole genome sequencing of Listeria, Salmonella, Campylobacter and E. coli isolates submitted to its lab and began uploading sequence data into PulseNet for nationwide monitoring of outbreaks and trends. In Fiscal Year 2018, Indiana will begin simultaneously monitoring these isolates for resistance genes. When outbreaks are detected, local CDC-supported epidemiologists investigate the cases to stop spread. $1,163,120 - GONORRHEA RAPID DETECTION & RESPONSE works with state and local epidemiology and laboratory partners to test for and quickly respond to resistant gonorrhea to stop its spread in high risk communities. Only one treatment option remains for gonorrhea and resistance continues to grow. With 2016 funding, Indiana increased their local response capacity and doubled their rapid susceptibility testing— which determines how well a gonorrhea strain will respond to specific antibiotics. Test results are used to inform local outbreak response action, national treatment guidelines and antibiotic resistance trends. Publication date from document properties. Indiana-2017-CDC-AR-Investments.pdf
  • Place as Subject:
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files

You May Also Like: